SAN FRANCISCO -- (Business Wire)
The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds
investors of the February 2, 2015 deadline to move for appointment as
lead plaintiff in the securities class action litigation brought on
behalf of investors who purchased or otherwise acquired the securities
of Sanofi (or the “Company”) (NYSE:SNY) between February 7, 2013 and
December 3, 2014, inclusive (the “Class Period”).
If you purchased or otherwise acquired Sanofi securities during the
Class Period, you may move the Court for appointment as lead plaintiff
by no later than February 2, 2015. A lead plaintiff is a representative
party who acts on behalf of other class members in directing the
litigation. Your share of any recovery in the action will not be
affected by your decision of whether to seek appointment as lead
plaintiff. You may retain Lieff Cabraser, or other attorneys, as your
counsel in the action.
Sanofi
investors who wish to learn more should click here or contact Sharon
M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.
The action charges Sanofi and certain of its current and former officers
with violations of the Securities Exchange Act of 1934. Sanofi is a
French pharmaceutical company that researches, develops and
manufacturers prescription pharmaceuticals and vaccines.
The complaint alleges that Sanofi, its Chief Executive Officer (“CEO”),
and its Chief Financial Officer (“CFO”) made false and misleading
statements and/or failed to disclose that the Company was making
improper payments to healthcare professionals in connection with the
sale of pharmaceutical products in violation of federal law.
On October 6, 2014, Sanofi announced that the Company was investing
allegations related to improper kick-back payments to healthcare workers
between 2007 and 2012. On October 29, 2014, Sanofi terminated its CEO,
defendant Christopher A. Viehbacher. On this news, Sanofi’s American
Depository Shares (“ADS”) fell $2.85 per share, or nearly 6 percent, in
heavy trading volume, to close at $45.22 per share.
On December 3, 2014, news outlets reported that a former paralegal at
the Company had filed a whistleblower lawsuit against Sanofi, alleging
that CEO Viehbacher and other executives had engaged in a kickback
scheme designed to funnel tens of millions of dollars to customers in
violation of federal law. On this news, Sanofi’s ADS fell another $1.36
per share to close at $46.75 on December 4, 2014.
About Lieff Cabraser
Lieff Cabraser is a nationally recognized law firm committed to
advancing the rights of investors and promoting corporate responsibility.
For eleven years, the National Law Journal has selected Lieff
Cabraser as one of the top plaintiffs’ law firms in the nation. Best
Lawyers and U.S. News have also named Lieff Cabraser as a
“Law Firm of the Year” each year the publications have given this award
to law firms.
For more information about Lieff Cabraser and the firm’s representation
of investors, please visit http://www.lieffcabraser.com.
Contacts:
Lieff Cabraser Heimann & Bernstein, LLP
Sharon M. Lee,
415-956-1000
Source: Lieff Cabraser Heimann & Bernstein, LLP
© 2024 Canjex Publishing Ltd. All rights reserved.